• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

West Pharmaceuticals dips despite strong Q3, raised guidance

October 22, 2020 By Sean Whooley

West Pharmaceutical Services - updated logoWest Pharmaceutical Services (NYSE:WST) shares dipped slightly despite third-quarter results that topped the consensus forecast.

The Exton, Pa.-based company posted profits of $82.3 million, or $1.09 per share, on sales of $548 million for the three months ended Sept. 30, 2020, for a 46.2% bottom-line gain on sales growth of 0.3%.

Adjusted to exclude one-time items, earnings per share were $1.15, 16¢ ahead of Wall Street, where analysts were looking for sales of $510.1 million

The company saw 22.1% growth in its proprietary products segment, with high-value product (HVP) components representing over 65% of segment sales, while its biologics market unit saw double-digit growth.

Contract-manufactured products chipped in with 14% growth in the segment with healthcare-related injection and diagnostic devices providing strong sales figures.

“Third-quarter results were robust across the entire business, led by HVP and biologics,” West president & CEO Eric Green said in a news release. “Additionally, we benefited from incremental sales related to the COVID-19 pandemic including components used with treatments and supporting therapies as well as potential vaccines currently in clinical trials.

“I am proud of our team members for their relentless passion and sense of urgency to help our customers and the patients we jointly serve. Continued excellence in executing our market-led strategy and our global operations position us well for the remainder of the year and into 2021.”

West said it now expects to log adjusted EPS of between $4.50 and $4.55, compared to a prior range of $4.15 and $4.25, and updated its prior sales guidance for between $2.10 billion and $2.11 billion.

WST shares were down -1.1% at $281.33 per share in mid-afternoon trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up 2.4%.

Filed Under: Business/Financial News, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: West Pharmaceutical Services

IN CASE YOU MISSED IT

  • FDA lifts hold on Vertex’s insulin-producing cell therapy for diabetes
  • Retractable Technologies declares dividends
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • West Pharmaceutical Services debuts new needle syringe system
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS